These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33871750)

  • 21. Advances in therapy for spinal muscular atrophy: promises and challenges.
    Groen EJN; Talbot K; Gillingwater TH
    Nat Rev Neurol; 2018 Apr; 14(4):214-224. PubMed ID: 29422644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nusinersen: A Treatment for Spinal Muscular Atrophy.
    Claborn MK; Stevens DL; Walker CK; Gildon BL
    Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Putting our best foot forward: Clinical, treatment-based and ethical considerations of nusinersen therapy in Canada for spinal muscular atrophy.
    Vukovic S; McAdam L; Zlotnik-Shaul R; Amin R
    J Paediatr Child Health; 2019 Jan; 55(1):18-24. PubMed ID: 30246272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
    Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
    Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treating adults with spinal muscular atrophy with nusinersen.
    Farrar MA; Kiernan MC
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1139. PubMed ID: 32917825
    [No Abstract]   [Full Text] [Related]  

  • 30. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
    Gidaro T; Servais L
    Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
    Meylemans A; De Bleecker J
    Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
    Li Q
    Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nusinersen for the treatment of spinal muscular atrophy.
    Chiriboga CA
    Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges.
    Messina S; Sframeli M
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32668756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1.
    Bruno G; Donnarumma B; Inverardi A; Buonpensiero P; Sepe A; Tosco A; Raia V; Varone A
    Pediatr Pulmonol; 2021 Jun; 56(6):1806-1808. PubMed ID: 33684256
    [No Abstract]   [Full Text] [Related]  

  • 38. Nusinersen for SMA: expanded access programme.
    Farrar MA; Teoh HL; Carey KA; Cairns A; Forbes R; Herbert K; Holland S; Jones KJ; Menezes MP; Morrison M; Munro K; Villano D; Webster R; Woodcock IR; Yiu EM; Sampaio H; Ryan MM
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):937-942. PubMed ID: 29549190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
    Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
    Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.